title: Rituximab in the treatment of bullous systemic lupus erythematosus.
abstract: Rituximab is a CD20 chimeric monoclonal antibody. It was approved by the US Food and Drug Administration for the treatment of relapsed or refractory low-grade or follicular non-Hodgkin lymphoma and for the treatment of moderate to severely active rheumatoid arthritis. It has been used as an off-label treatment in many autoimmune diseases, where B cells play a major role in the pathogenesis. We report a case of successful use of rituximab in the treatment of refractory bullous systemic lupus erythematosus in an African American patient.
authors: Philadelphia VA Medical Center, Philadelphia, PA, USA. dr_shamael@yahoo.com
authors: Shamael
authors: S
authors: Alsanafi
authors: Carrie
authors: C
authors: Kovarik
authors: Andrew L
authors: AL
authors: Mermelstein
authors: Victoria P
authors: VP
authors: Werth
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab